Identification

Name
Dapiprazole
Accession Number
DB00298  (APRD00902)
Type
Small Molecule
Groups
Approved
Description

Dapiprazole (U.S. trade name Rev-Eyes) is an alpha blocker. It is used to reverse mydriasis after eye examination. [Wikipedia]

Structure
Thumb
Synonyms
  • 5,6,7,8-Tetrahydro-3-(2-(4-(O-tolyl)-1-piperazinyl)ethyl)-S-triazolo(4,3-a)pyridine
  • Dapiprazol
  • Dapiprazolum
Product Ingredients
IngredientUNIICASInChI Key
Dapiprazole hydrochlorideDS9UJN1I0X72822-13-0ZIODNPFQZIHCOE-UHFFFAOYSA-N
International/Other Brands
Rev-Eyes
Categories
UNII
5RNZ8GJO7K
CAS number
72822-12-9
Weight
Average: 325.4512
Monoisotopic: 325.226645889
Chemical Formula
C19H27N5
InChI Key
RFWZESUMWJKKRN-UHFFFAOYSA-N
InChI
InChI=1S/C19H27N5/c1-16-6-2-3-7-17(16)23-14-12-22(13-15-23)11-9-19-21-20-18-8-4-5-10-24(18)19/h2-3,6-7H,4-5,8-15H2,1H3
IUPAC Name
1-(2-methylphenyl)-4-(2-{5H,6H,7H,8H-[1,2,4]triazolo[4,3-a]pyridin-3-yl}ethyl)piperazine
SMILES
CC1=CC=CC=C1N1CCN(CCC2=NN=C3CCCCN23)CC1

Pharmacology

Indication

Used in the treatment of iatrogenically induced mydriasis produced by adrenergic (phenylephrine) or parasympatholytic (tropicamide) agents used in certain eye examinations.

Structured Indications
Not Available
Pharmacodynamics

Dapiprazole is an alpha-adrenergic blocking agent. It produces miosis by blocking the alpha-adrenergic receptors on the dilator muscle of the iris. Dapiprazole produces no significant action on ciliary muscle contraction and thus, there are no changes in the depth of the anterior chamber of the thickness of the lens. It does not alter the IOP either in normal eyes or in eyes with elevated IOP. The rate of pupillary constriction may be slightly slower in clients with brown irises than in clients with blue or green irises.

Mechanism of action

Dapiprazole acts through blocking the alpha1-adrenergic receptors in smooth muscle. It produces miosis through an effect on the dilator muscle of the iris and does not have any significant activity on ciliary muscle contraction and, therefore does not induce a significant change in the anterior chamber depth or the thickness of the lens.

TargetActionsOrganism
AAlpha-1A adrenergic receptor
antagonist
Human
AAlpha-1D adrenergic receptor
antagonist
Human
AAlpha-1B adrenergic receptor
antagonist
Human
Absorption

Systemic absorption is negligible.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity

Oral LD50 is 1189-2100 mg/kg in mice, rats and rabbits.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamineDapiprazole may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3,4-MethylenedioxyamphetamineDapiprazole may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineDapiprazole may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with 7-Nitroindazole.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Aceprometazine.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Dapiprazole.Approved, Illicit
AllopregnanoloneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Allopregnanolone.Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Dapiprazole.Approved, Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Dapiprazole.Approved, Illicit, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Amitriptyline.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Dapiprazole.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Amperozide.Experimental
AmphetamineDapiprazole may decrease the stimulatory activities of Amphetamine.Approved, Illicit
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Dapiprazole.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Dapiprazole.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Azaperone.Vet Approved
AzelastineDapiprazole may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Barbital.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Benzocaine.Approved
BenzphetamineDapiprazole may decrease the stimulatory activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Benzyl alcohol.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Brexpiprazole.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Dapiprazole.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Dapiprazole.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Bromisoval.Experimental
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Dapiprazole.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Bromperidol.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Brotizolam.Approved, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Dapiprazole.Approved, Investigational
BuprenorphineDapiprazole may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Dapiprazole.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Dapiprazole.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Dapiprazole.Approved, Illicit, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Dapiprazole.Approved
CanertinibThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Canertinib.Investigational
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Dapiprazole.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Carfentanil.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Carisoprodol.Approved
CetirizineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Dapiprazole.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Chlormezanone.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Chloroprocaine.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Chlorphenamine.Approved
ChlorphentermineDapiprazole may decrease the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Dapiprazole.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Chlorprothixene.Approved, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Chlorzoxazone.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Cinchocaine.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Citalopram is combined with Dapiprazole.Approved
ClemastineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Clopenthixol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Dapiprazole.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Clothiapine.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Dapiprazole.Approved
CocaineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Dapiprazole.Approved, Illicit
CyclizineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Dapiprazole.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Cyproheptadine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Dantrolene.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Dapoxetine.Investigational
DeramciclaneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Dapiprazole.Approved
DesipramineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Dapiprazole.Approved
DetomidineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Dexmedetomidine.Approved, Vet Approved
DextroamphetamineDapiprazole may decrease the stimulatory activities of Dextroamphetamine.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Dapiprazole.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Dextropropoxyphene.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Dezocine.Approved
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Dapiprazole.Approved, Illicit, Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Diethyl ether.Experimental
DiethylpropionDapiprazole may decrease the stimulatory activities of Diethylpropion.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Dapiprazole.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Dapiprazole.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Dihydromorphine.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Dapiprazole.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Dapiprazole.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Dixyrazine.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Doxepin.Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Dapiprazole.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Dapiprazole is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Dapiprazole.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Dapiprazole.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Dapiprazole.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Dyclonine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Ecgonine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Efavirenz.Approved, Investigational
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Dapiprazole.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Eltanolone.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Dapiprazole.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Entacapone.Approved, Investigational
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Dapiprazole.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Dapiprazole.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Dapiprazole.Approved
EscitalopramThe risk or severity of adverse effects can be increased when Escitalopram is combined with Dapiprazole.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Dapiprazole.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Dapiprazole.Approved
EthanolDapiprazole may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dapiprazole.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Ethyl chloride.Experimental
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Dapiprazole.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Etorphine.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Fencamfamine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Dapiprazole.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Flibanserin.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Fluanisone.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Dapiprazole.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Dapiprazole.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Dapiprazole.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Dapiprazole.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Fluspirilene.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Fluticasone propionate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Dapiprazole.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Fospropofol.Approved, Illicit
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Dapiprazole.Approved, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Dapiprazole.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Gabapentin Enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Dapiprazole.Approved, Illicit
GepefrineDapiprazole may decrease the stimulatory activities of Gepefrine.Experimental
GepironeThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Glutethimide.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Dapiprazole.Approved
HalothaneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Heroin.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Hexobarbital.Approved
HydrocodoneDapiprazole may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Dapiprazole.Approved, Illicit
HydroxyamphetamineDapiprazole may decrease the stimulatory activities of Hydroxyamphetamine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Dapiprazole.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Iloperidone.Approved
ImipramineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Indalpine.Investigational, Withdrawn
IndiplonThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Indiplon.Investigational
Iofetamine I-123Dapiprazole may decrease the stimulatory activities of Iofetamine I-123.Approved
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Dapiprazole.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Dapiprazole.Approved, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Dapiprazole.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Ketobemidone.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Lamotrigine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Levobupivacaine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Levomethadyl Acetate.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Dapiprazole.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Dapiprazole.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Dapiprazole.Approved, Vet Approved
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Dapiprazole.Approved, Investigational
LisdexamfetamineDapiprazole may decrease the stimulatory activities of Lisdexamfetamine.Approved, Investigational
LithiumLithium may increase the neurotoxic activities of Dapiprazole.Approved
LofentanilThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Lofentanil.Illicit
LoprazolamThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Dapiprazole.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Dapiprazole.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Lormetazepam.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Dapiprazole.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Dapiprazole.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Dapiprazole.Approved, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Maprotiline.Approved
MebicarThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Mebicar.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Melperone.Approved
MephedroneDapiprazole may decrease the stimulatory activities of Mephedrone.Investigational
MephentermineDapiprazole may decrease the stimulatory activities of Mephentermine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Dapiprazole.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Meptazinol.Experimental
MequitazineDapiprazole may increase the arrhythmogenic activities of Mequitazine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Mesoridazine.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Dapiprazole.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineDapiprazole may decrease the stimulatory activities of Methamphetamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Dapiprazole.Approved
MethotrimeprazineDapiprazole may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Methoxyflurane.Approved, Vet Approved
MethoxyphenamineDapiprazole may decrease the stimulatory activities of Methoxyphenamine.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Methsuximide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Methylecgonine.Experimental
MethylphenidateThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Methylphenobarbital.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Dapiprazole.Approved, Investigational
MetyrosineDapiprazole may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Dapiprazole.Approved, Illicit
MidomafetamineDapiprazole may decrease the stimulatory activities of 3,4-Methylenedioxymethamphetamine.Experimental, Illicit
MilnacipranThe risk or severity of adverse effects can be increased when Milnacipran is combined with Dapiprazole.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Dapiprazole.Approved, Investigational
MirtazapineDapiprazole may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MMDADapiprazole may decrease the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Dapiprazole.Approved
MolindoneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Molindone.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Dapiprazole.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Dapiprazole.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Dapiprazole.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Dapiprazole.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Dapiprazole.Approved, Withdrawn
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Dapiprazole.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Dapiprazole.Approved, Vet Approved
NorfluraneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Norflurane.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Nortriptyline.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Dapiprazole.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Opium.Approved, Illicit
OrphenadrineDapiprazole may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Osanetant.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Dapiprazole.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Oxethazaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Oxybuprocaine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Dapiprazole.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Dapiprazole.Approved, Investigational, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Dapiprazole.Approved
ParaldehydeDapiprazole may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Dapiprazole.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Penfluridol.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Dapiprazole.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Dapiprazole.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Dapiprazole.Approved
PerazineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Dapiprazole.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Dapiprazole.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Phenazocine.Experimental
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Dapiprazole.Approved
PhenibutThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Phenibut.Experimental
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Dapiprazole.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Phenoperidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Phenoxyethanol.Approved
PhentermineDapiprazole may decrease the stimulatory activities of Phentermine.Approved, Illicit
PhenytoinThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Dapiprazole.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Pipamperone.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Pipotiazine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Pomalidomide.Approved
PramipexoleDapiprazole may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Prazepam.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Dapiprazole.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Prilocaine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Procaine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Dapiprazole.Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Dapiprazole.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Dapiprazole.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Promethazine.Approved
PropanididThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Proparacaine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Dapiprazole.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Propoxycaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Protriptyline.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when Dapiprazole is combined with PSD502.Investigational
PseudoephedrineDapiprazole may decrease the stimulatory activities of Pseudoephedrine.Approved
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Dapiprazole.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Dapiprazole.Approved
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Dapiprazole.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Ramelteon.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Dapiprazole.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Dapiprazole.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Remoxipride.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Dapiprazole.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Dapiprazole.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Ritanserin.Investigational
RitobegronDapiprazole may decrease the stimulatory activities of Ritobegron.Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Dapiprazole.Approved
RomifidineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Romifidine.Vet Approved
RopiniroleDapiprazole may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Dapiprazole.Approved
RotigotineDapiprazole may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Dapiprazole.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Dapiprazole.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Dapiprazole.Approved, Investigational, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Sertindole.Approved, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Dapiprazole.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Dapiprazole.Approved, Vet Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Dapiprazole.Approved
StiripentolThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Dapiprazole.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Sulpiride.Approved
SultoprideThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Sultopride.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Dapiprazole.Approved, Investigational
SuvorexantDapiprazole may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Dapiprazole.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Tasimelteon.Approved
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Dapiprazole.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Dapiprazole.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Dapiprazole.Approved
TetracaineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Tetrodotoxin.Investigational
ThalidomideDapiprazole may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Thiopental.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Dapiprazole.Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Dapiprazole.Approved
TiagabineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Tiapride.Approved, Investigational
TiletamineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Tilidine.Experimental
TizanidineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Tizanidine.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Tolcapone.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Dapiprazole.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Tranylcypromine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Trazodone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Dapiprazole.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Trichloroethylene.Experimental
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Dapiprazole.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Triflupromazine.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Triprolidine.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Valproic Acid.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Dapiprazole.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Veralipride.Experimental
VigabatrinThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Vigabatrin.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Dapiprazole.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Vinyl ether.Experimental
VortioxetineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Vortioxetine.Approved
XenonThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Dapiprazole.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Dapiprazole.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Dapiprazole.Approved, Investigational
ZolpidemDapiprazole may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Dapiprazole.Approved
ZotepineThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Zotepine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Dapiprazole.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference
Not Available
General References
Not Available
External Links
Human Metabolome Database
HMDB14443
PubChem Compound
3033538
PubChem Substance
46508859
ChemSpider
2298190
ChEBI
51066
ChEMBL
CHEMBL1201216
Therapeutic Targets Database
DAP000298
PharmGKB
PA164749109
Drugs.com
Drugs.com Drug Page
Wikipedia
Dapiprazole
ATC Codes
S01EX02 — Dapiprazole
AHFS Codes
Not Available
PDB Entries
Not Available
FDA label
Not Available
MSDS
Download (114 KB)

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
  • Angelini pharmaceuticals inc
Packagers
  • American Cyanamid Co.
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
water solubilitySolubleNot Available
logP2.3Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.751 mg/mLALOGPS
logP2.78ALOGPS
logP2.42ChemAxon
logS-2.6ALOGPS
pKa (Strongest Basic)7.67ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area37.19 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity100.22 m3·mol-1ChemAxon
Polarizability38.23 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9832
Caco-2 permeable+0.5899
P-glycoprotein substrateSubstrate0.657
P-glycoprotein inhibitor IInhibitor0.8074
P-glycoprotein inhibitor IIInhibitor0.9107
Renal organic cation transporterInhibitor0.7481
CYP450 2C9 substrateNon-substrate0.8296
CYP450 2D6 substrateNon-substrate0.5563
CYP450 3A4 substrateSubstrate0.5833
CYP450 1A2 substrateInhibitor0.6905
CYP450 2C9 inhibitorNon-inhibitor0.5324
CYP450 2D6 inhibitorNon-inhibitor0.632
CYP450 2C19 inhibitorInhibitor0.7506
CYP450 3A4 inhibitorInhibitor0.7338
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.9357
Ames testNon AMES toxic0.6215
CarcinogenicityNon-carcinogens0.8546
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.7573 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.6592
hERG inhibition (predictor II)Inhibitor0.7292
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenylpiperazines. These are compounds containing a phenylpiperazine skeleton, which consists of a piperazine bound to a phenyl group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Diazinanes
Sub Class
Piperazines
Direct Parent
Phenylpiperazines
Alternative Parents
N-arylpiperazines / Triazolopyridines / Dialkylarylamines / Aniline and substituted anilines / Aminotoluenes / N-alkylpiperazines / Aralkylamines / Pyridines and derivatives / Triazoles / Heteroaromatic compounds
show 4 more
Substituents
Phenylpiperazine / N-arylpiperazine / Triazolopyridine / Tertiary aliphatic/aromatic amine / Dialkylarylamine / Aniline or substituted anilines / Aminotoluene / Aralkylamine / N-alkylpiperazine / Toluene
show 16 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
N-arylpiperazine, pyridines, N-alkylpiperazine (CHEBI:51066)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1A
Uniprot ID
P35348
Uniprot Name
Alpha-1A adrenergic receptor
Molecular Weight
51486.005 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Eltze M: Affinity of the miotic drug, dapiprazole, at alpha 1-adrenoceptor subtypes A, B and D. J Pharm Pharmacol. 1997 Nov;49(11):1091-5. [PubMed:9401944]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Alpha1-adrenergic receptor activity
Specific Function
This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium.
Gene Name
ADRA1D
Uniprot ID
P25100
Uniprot Name
Alpha-1D adrenergic receptor
Molecular Weight
60462.205 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1B
Uniprot ID
P35368
Uniprot Name
Alpha-1B adrenergic receptor
Molecular Weight
56835.375 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]

Drug created on June 13, 2005 07:24 / Updated on October 02, 2017 04:34